These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38861267)

  • 1. Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation.
    Royston L; Neofytos D
    Curr Opin Infect Dis; 2024 Aug; 37(4):264-269. PubMed ID: 38861267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting Cytomegalovirus Serology in Allogeneic Hematopoietic Cell Transplant Recipients.
    Portillo V; Masouridi-Levrat S; Royston L; Yerly S; Schibler M; Mappoura M; Morin S; Giannotti F; Mamez AC; van Delden C; Chalandon Y; Neofytos D
    Clin Infect Dis; 2024 Feb; 78(2):423-429. PubMed ID: 37713176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients.
    Talaya A; Giménez E; Vinuesa V; Pérez A; Amat P; Piñana JL; Albert E; Hernández-Boluda JC; Solano C; Navarro D
    Med Microbiol Immunol; 2019 Aug; 208(3-4):405-414. PubMed ID: 30911925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawamura S; Nakasone H; Takeshita J; Kimura SI; Nakamura Y; Kawamura M; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Akahoshi Y; Kusuda M; Kameda K; Tanihara A; Tamaki M; Kako S; Kanda Y
    Transplant Cell Ther; 2021 Aug; 27(8):683.e1-683.e7. PubMed ID: 33984537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
    Perry DA; Hakki M
    Transpl Infect Dis; 2016 Oct; 18(5):809-814. PubMed ID: 27502917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients.
    Pascual T; Solano C; Torres I; Talaya A; Giménez E; Vinuesa V; Piñana JL; Hernández-Boluda JC; Pérez A; Navarro D
    J Med Virol; 2018 Aug; 90(8):1375-1382. PubMed ID: 29663435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes.
    Talaya A; Giménez E; Piñana JL; Albert E; Hernández-Boluda JC; Pérez A; Torres I; Solano C; Navarro D
    J Med Virol; 2019 Jun; 91(6):1128-1135. PubMed ID: 30735250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting.
    Giménez E; Blanco-Lobo P; Muñoz-Cobo B; Solano C; Amat P; Pérez-Romero P; Navarro D
    J Gen Virol; 2015 Sep; 96(9):2822-2831. PubMed ID: 26025872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
    Thiele T; Krüger W; Zimmermann K; Ittermann T; Wessel A; Steinmetz I; Dölken G; Greinacher A
    Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.
    Eberhardt KA; Jung V; Knops E; Heger E; Wirtz M; Steger G; Kaiser R; Affeldt P; Holtick U; Klein F; Scheid C; Di Cristanziano V
    Bone Marrow Transplant; 2023 Jun; 58(6):639-646. PubMed ID: 36869190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
    Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
    Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide.
    Huntley D; Giménez E; Pascual MJ; Hernández-Boluda JC; Gago B; Vázquez L; Piñana JL; García M; Pérez A; Serrano D; Hernández M; Albert E; Solano C; Navarro D
    Transpl Infect Dis; 2020 Feb; 22(1):e13206. PubMed ID: 31677215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
    Reed DR; Petroni GR; West M; Jones C; Alfaraj A; Williams PG; DeGregory K; Grose K; Monson S; Varadarajan I; Volodin L; Donowitz GR; Kindwall-Keller TL; Ballen KK
    Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):61-69. PubMed ID: 36634280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation.
    Piñana JL; Perez-Pitarch A; Guglieri-Lopez B; Giménez E; Hernandez-Boluda JC; Terol MJ; Ferriols-Lisart R; Solano C; Navarro D
    Am J Transplant; 2018 Dec; 18(12):2885-2894. PubMed ID: 29603596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.